share_log

HC Wainwright & Co. Reiterates Buy on SpringWorks Therapeutics, Maintains $74 Price Target

Benzinga ·  May 6 06:35

HC Wainwright & Co. analyst Robert Burns reiterates SpringWorks Therapeutics (NASDAQ:SWTX) with a Buy and maintains $74 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment